WO1994003584A1 - Production of graft tissue from extracellular matrix - Google Patents

Production of graft tissue from extracellular matrix Download PDF

Info

Publication number
WO1994003584A1
WO1994003584A1 PCT/US1993/007364 US9307364W WO9403584A1 WO 1994003584 A1 WO1994003584 A1 WO 1994003584A1 US 9307364 W US9307364 W US 9307364W WO 9403584 A1 WO9403584 A1 WO 9403584A1
Authority
WO
WIPO (PCT)
Prior art keywords
connective tissue
particulates
polymer
cells
thread
Prior art date
Application number
PCT/US1993/007364
Other languages
French (fr)
Inventor
Eugene Bell
Original Assignee
Tissue Engineering, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tissue Engineering, Inc. filed Critical Tissue Engineering, Inc.
Priority to EP93919888A priority Critical patent/EP0656939B1/en
Priority to DE69333466T priority patent/DE69333466T2/en
Priority to JP6505561A priority patent/JPH07509638A/en
Publication of WO1994003584A1 publication Critical patent/WO1994003584A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A61L27/3691—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment characterised by physical conditions of the treatment, e.g. applying a compressive force to the composition, pressure cycles, ultrasonic/sonication or microwave treatment, lyophilisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Definitions

  • a third approach has been that of reconstituting tissue and organ equivalents from structural matrix components, such as collagen, for example, that have been extracted and purified and combined with specialized cells. The process depends upon interactions between the cells and matrix proteins that the cells condense and organize. While tissue-like constructs have been fabricated and been shown to somewhat resemble their natural counterparts, they do not readily develop the matrix complexity characteristic of the actual tissues they are meant to imitate. See, for example, U.S. Patent Nos. 4,485,096 and 4,485,097, E. Bell, 1984.
  • the present invention relates to a method of producing graft tissue by obtaining a desired connective tissue source and processing it to remove living cells without removing factors necessary for cell growth.
  • the tissue is frozen or freeze dried and then fragmented, and the living cells removed to produce connective tissue matrix particulates.
  • the tissue can be fragmented before freezing.
  • the invention also includes methods of producing graft tissue which comprise the above method with the additional steps, alone or in combination, of 1) again processing the connective tissue particulates to remove the cytoplasmic and nucleic acid components without removing the factors necessary for cell growth and differentiation; and 2) seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to or populate the connective tissue particulates.
  • the matrix particulates are seeded with selected cultured human or other cells.
  • the resulting cell populated material can be fused into composites of various shapes, with or without the addition of growth and differentiation factors.
  • the present invention embodies a new method for preparing animal tissues as transplants designed to substitute for tissues or organs that are damaged or diseased. This is accomplished in such a way that their native complexity is preserved and thus allows them to be remodeled and integrated by the specialized cells with which they are brought into contact.
  • the matrix particulates of the present invention contain cell growth and differentiation stimulatory molecules, they provide the biomolecular signals needed for -in vivo tissue repair.
  • the method of the present invention avoids the use of harsh reagents such as high salt, or delipidation reagents such as butanol/ether or detergents.
  • harsh reagents such as high salt, or delipidation reagents such as butanol/ether or detergents.
  • delipidation reagents such as butanol/ether or detergents.
  • the present invention can be used to bring a disease such as diabetes under control by engineering and implanting reconstituted tissues or composites populated by cells with the appropriate functional capacity to overcome the problems caused by absent or insufficient insulin biosynthesis or its regulated delivery.
  • particulates of the present invention can be combined in vitro with cells from the islets of Langerhans, or with undissociated islets, to form a composite which is then implanted under the kidney capsule.
  • cell-populated matrix composites may be implanted directly, for example by using a hypodermic syringe or similar devise to deliver the composite to the desired site.
  • This invention similarly may be used to treat Parkinson's disease by providing the patient with a tissue containing dopamine producing cells.
  • tissue containing dopamine producing cells One can also plate nerve cells on the particulates and allow a composite to form. This would be useful in the repair of neural tissue defects.
  • the method of this invention also has broad applications in the rebuilding of damaged or aberrant body structures such as skin, various tubular structures and skeletal structures such as bone, tendon and ligament.
  • the invention may also be used to create connective tissue matrices to be used as tissue scaffolds which are populated by circulating cells after transplantation into the desired site.
  • the matrix particulates are mixed with a substance which can form porous membranous polymers containing the particulates, and then shaped.
  • Matrix particulate-containing threads are one example of the many shapes which can be formed using particulates of the present invention.
  • the particulates can be mixed with collagen, or another bioabsorbable or nonbioabsorbable polymer, and extruded into a dehydration or coagulation bath containing absolute ethanol or acetone, or another dehydrating solution.
  • the thread can also be subjected to dehydration by some other means, for example vacuum-drying.
  • the particulates can also be coextruded with collagen or another polymer serving as a hollow fiber.
  • the particulates and the hollow fiber serve as a loaded hollow fiber with the particulates filling the core of the hollow polymer fiber.
  • the threads produced in this manner can then be braided or woven to form fabrics or other complex constructs for implantation.
  • sleeves of the loaded hollow fiber threads can be made porous, thus allowing colonizing cells to occupy the surface of the thread and thereby contact the tissue matrix particles within the thread.
  • the method of the present invention is used to produce matrix particulates from fetal skeletal elements derived from animal sources, prior to mineralization.
  • fetal matrix particulates can be combined with osteogenic cells in cylindrically shaped collagenous containers to form skeletal constructs.
  • the collagenous external surface of the containers can be plated with a second cell type associated with periosteal tissue.
  • a composite derived from dermal matrix particulates, or from a sheet of previously frozen matrix that has been perforated can be over-plated with keratinocytes to form a skin-like construct.
  • the invention includes a method of producing graft tissue which comprises obtaining a desired connective tissue source, then processing it to remove living cells without removing factors necessary for cell growth and differentiation.
  • the cell-free connective tissue source is frozen or freeze-dried, and fragmented, either before or after freezing or freeze-drying, to produce connective tissue particulates.
  • the tissue can be frozen or freeze-dried after fragmentation.
  • the cell-free connective tissue particulates can be used as an implant for host cells to populate.
  • the freeze-dried connective tissue can also be used without fragmentation, but perforated before use.
  • the cell-free tissue can be used in the form of perforated sheets or strips without fragmentation.
  • the invention includes another method for producing graft tissue which comprises obtaining a desired connective tissue source and processing as above to remove living cells without removing factors necessary for cell growth and differentiation.
  • the connective tissue source is frozen or freeze-dried, then fragmented to produce connective tissue particulates.
  • the connective tissue particulates are seeded with cultivated cells under such conditions that the cells adhere to and populate the connective tissue particulates.
  • the connective tissue particulates are seeded with cultivated cells and then packed into a preformed porous polymeric container.
  • This method can also include the optional step of further processing the connective tissue particulates before they are seeded, in order to remove nucleic acids without removing other factors necessary for cell growth and differentiation.
  • Further processing can include contacting the connective tissue particulates with nuclease preparations.
  • the invention includes another method for producing graft tissue which comprises obtaining a desired connective tissue source and processing as above to remove living cells without removing factors necessary for cell growth and differentiation.
  • the connective tissue source is then frozen or freeze-dried and fragmented to produce connective tissue particulates.
  • the cells can be removed prior to fragmentation.
  • the particulates are mixed with a porous polymer, such as collagen or other bioabsorbable or nonbioabsorbable polymers, then extruded to form threads composed of the polymer and the connective tissue particulates.
  • the threads of the invention can be either mixed fiber (in which the thread is comprised of a mixture of the polymer and the cell matrix particulate) , or loaded hollow fiber (in which the thread is comprised of a core of cell matrix particulates surrounded by a porous polymer sleeve) . These threads are then braided or woven to form fabrics or other complex constructs for implantation. The sleeve of the loaded hollow fiber threads is porous, thus allowing colonizing cells to occupy the surface of the thread and thereby contact the tissue matrix particles within the thread.
  • the invention encompasses another method of producing graft tissue which comprises obtaining a desired connective tissue' source and processing to remove living cells without removing factors necessary for cell growth and differentiation.
  • the connective tissue source is frozen or freeze-dried, but not fragmented. Instead, the tissue is processed in the form of sheets or strips. These sheets or strips are frozen or freeze-dried, then thawed and perforated to allow cells to infiltrate the tissue.
  • the connective tissue sheets or strips are seeded with cultivated cells under such conditions that the cells adhere to and populate the sheets or strips.
  • the seeded sheets or strips can be further shaped or molded to form useful graft tissue.
  • the sheets or strips can be implanted into a host without first seeding with cultivated cells. According to this embodiment, the sheets or strips would provide a site for host cells to populate.
  • Fragmentation of the desired tissue can be achieved by freezing or freeze-drying, and then mechanically blending the frozen or freeze-dried tissue or mechanically crushing it between rollers.
  • the desired tissue can also be fragmented by blending the tissue without first freezing it.
  • An optional nuclease treatment is carried out for the purpose of digesting the nucleic acids released when the cells and cell nuclei are ruptured.
  • the connective tissue particulates are then washed and collected by the serial steps of centrifugation, resuspension, recentrifugation and resuspension.
  • the invention further encompasses a method wherein the connective tissue particulates obtained by the above methods are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates.
  • One embodiment of this method includes an additional step of fusing the connective tissue particulates to form a composite using a fusing agent.
  • the type of fusing agents which can be selected are known to one skilled in the art.
  • in vitro cultivated cells are plated onto the connective tissue composite in a volume which will just cover the composite and allow transportation of nutrients. The cells are plated under conditions that allow the cells to populate or adhere to the connective tissue particulates.
  • One or more than one cell type can be plated onto the composite.
  • the invention further includes a construct which is produced by any of the above methods, including a multi- cell construct.
  • the connective tissue source can be derived from bovine, ovine, porcine or marine animal connective tissues, as well as other species of vertebrates of invertebrates.
  • the invention further includes connective tissues which are derived from a variety of body parts or tissues.
  • connective tissue is derived from embryonic or fetal tissues.
  • Embryonic and fetal tissues are advantageous because they include various biomolecular factors which are present in normal tissue at different stages of cell development.
  • the factors present in fetal tissues include, for example, factors necessary for cell division, differentiation and tissue morphogenesis.
  • the connective tissue matrix particulates derived through the above methods can be seeded with selected cultured human or other cells.
  • the resulting cell- populated matrix can be fused into composites of various shapes, with or without the addition of growth and differentiation factors.
  • the matrix particulates are selected to match the tissue being fabricated.
  • a skin replacement is the objective, preferably dermal matrix would be particularized and a composite with dermal cells constructed.
  • neural tissue replacement is the goal, preferably embryonic or fetal central nervous system connective tissue matrix would be chosen for combination with the appropriate cells to form a composite.
  • the processing steps of the above methods are performed in order to remove cells from the selected animal tissues, thereby producing connective tissue matrix particulates.
  • the choice of method and the sequence of treatments depend on the type of tissue being processed.
  • the tissue is scraped with a blade or blade-like instrument.
  • the tissue can also be passed successively between parallel rollers, where the rollers are brought closer together in successive steps thereby squeezing out soft components including cells.
  • the tissue can also be treated with enzymes, particularly nucleases. Additionally, the tissue is passed through a freeze-thaw, or freeze-dry-thaw cycle in order to disrupt the living cells. These methods can also be employed to remove remaining cytoplasmic and nuclear components in connective tissue particulates produced by fragmentation of the connective tissue source.
  • the freezing and/or freeze-drying, and fragmentation steps are done to produce particulates and to further free the tissue of undesirable components.
  • Methods for sterilizing processed tissues are known to one skilled in the art and include contacting the tissue with a peracetic acid solution, preferably about a 0.5% solution, and washing the tissue in a sterile buffer, preferably sterile phosphate buffered saline.
  • the tissue can then be freeze- dried by being brought to the temperature of liquid nitrogen, then fragmented under sterile conditions. Fragmentation at low temperature can be carried out in many ways known to those skilled in the art.
  • Fragmentation methods could include a shearing device, such as a mechanical blender, or mechanically crushing the tissue between rollers to yield particulates of such a size so as to allow for vascularization upon implantation.
  • the particulates are between about 50 and about 300 micrometers in diameter, but for some applications the particulates can be as small as 5-10 microns.
  • further nuclease cleaning and washes followed by centrifugation and resuspension in fresh phosphate buffered saline can be carried out in an effort to minimize the presence of components which are immunogenic.
  • the tissue can be dehydrated chemically with acetone, absolute alcohol or hydrophilic polymers such as carbowax, and then fragmented.
  • the particulates are further treated by seeding the matrix with cells. Preferably one would use human cells for populating the matrix, but the invention is not limited to hu an cells.
  • the seeding process is carried out by rehydrating the matrix particulates using tissue culture medium, with or without growth and differentiation supplements added, and allowing the particulates to swell to equilibrium with their fluid environment.
  • the matrix particulates are populated with cells of one, or more than one phenotype in a bioreactor, spinner flask or other similar device.
  • the number of cells used and the time of residence in the device depend on cell attachment time and the desired degree of coverage of the particulate by the cells. These parameters will vary depending on the type of cell used and the cell density required for the final product. The particular parameters for each cell type will be apparent to one skilled in the art.
  • the starting cell density is on the order of about 10 4 to about 10° cell per ml.
  • the particulates are fused into composites of various shapes with or without the addition of growth and differentiation factors.
  • This step can be carried out on particulates which have been seeded with cells, or on particulates which do not contain cells.
  • the fused matrix composite can be seeded with cells after the particulates are fused into composites.
  • the matrix composite, with or without cells, is then layered onto a synthetic porous membrane.
  • a synthetic porous membrane for illustrative purpose only and not to limit the invention in any way, include membranes made of polycarbonate, for example in a transwell arrangement, or a bioabsorbable polymer, such as a porous collagen sheet that lines a mold having a porous membrane for a bottom to hold the collagen sheet and permit passage of medium from below.
  • the membrane may also be made of other bioabsorbable polymers such as poly-1-lactate.
  • the particulates are layered in a single layer. In a preferred embodiment the layer is less than about 0.5 millimeters in thickness.
  • the thickness of the layer must be controlled in such a way so as to ensure that the necessary nutrients may flow to the cells.
  • the seeding of the matrix is carried out by applying cells in suspension directly onto the particulate composite in a volume that will just cover the composite but not run off it, under such conditions that the cells populate the matrix.
  • Non-limiting examples of a few of the ways in which the porosity of the composites can be controlled include: limiting cell growth, limiting crosslinking, and mechanically, by placing a brush-like device with spaced TeflonTM "hairs' 1 onto the substrate prior to delivering the particulates to it. If the last expedient is used the sheet will form around the microposts or "hairs", thereby creating holes when the "hairs" are removed.
  • the construct will be in the form of a coherent sheet that can be handled alone or, for example, by the porous collagen membrane on which it formed. In a preferred embodiment of the invention the incubation period is about 7-14 days.
  • the collagen membrane can also be used to wrap the composite.
  • the collagen membrane can be fixed to the composite, for example by suturing, so that a flat package is formed.
  • the sheet can also be rolled around a shaft to form a tube at ⁇ .ny stage in its development after it becomes coherent.
  • a further embodiment of the invention includes the use of multiple cell types combined with the composite by plating cells on either side of the composite, or by plating cells on the porous collagen membrane used to wrap the composite. Further, a layer of one cell type can be plated over a layer containing another cell type, or cells of different types may be plated together.
  • the invention encompasses the case where the cell-laden particulates are packaged in a preformed porous collagen or other polymeric container of any desired shape.
  • the container can be a rectangular box where, in a preferred embodiment, the box is not thicker than about 1.0mm.
  • the invention discloses the use of concentric tubes of differing radii where, in a preferred embodiment, the radii would differ by only by about 1.0mm or less. It is also envisioned that other shapes can be used as well.
  • the containers can be reinforced by struts or other means to maintain uniform thickness.
  • the frequency of the struts is preferably about 1-10 per mm square.
  • the container can be made out of a collagen sheet with pores which are too small to allow particulates to escape. In a preferred embodiment, the pores measure about 30 to about 60 microns. After introduction of particulates through an end opening, the container can be sealed by suturing or other means.
  • the connective tissue particulates are formed into threads suitable for weaving or braiding.
  • the threads can be woven into fabrics or other complex constructs for implantation, the braided or woven fabrics would provide a scaffold of matrix material for host cells to adhere to.
  • the thread or fabrics produced from the threads can be seeded with cells n vitro, as above, and then transplanted into the appropriate site in the host.
  • the threads of this invention can be either of the mixed fiber, or the loaded hollow type. Mixed fiber threads are made by mixing connective tissue particulates with a bioabsorbable or nonbioabsorbable polymer, then extruding the mixture, using, for example, a spinnaret, to form a mixed thread.
  • the hollow fiber thread comprises a core of connective tissue particles of this invention surrounded by a porous polymeric sleeve.
  • the polymer used for producing the threads can be either bioabsorbable or nonbioabsorbable. In a preferred embodiment the polymer is collagen.
  • threads of this invention are dehydrated and coagulated, for example by extrusion into a bath containing absolute alcohol, carbowax or acetone.
  • the threads can then be annealed, for example by pulling the threads over rollers from the coagulation bath into an annealing bath containing a saline solution.
  • the threads can then be dried and spooled, for example by pulling the threads over more rollers to dry, and then winding onto spools.
  • Animal sources are obtained for connective tissue matrix materials, such as organs, from porcine, bovine, ovine, marine or other animals.
  • connective tissue matrix materials such as organs, from porcine, bovine, ovine, marine or other animals.
  • organs such as porcine, bovine, ovine, marine or other animals.
  • the first is the pancreas itself, which would provide the tissue specificity of the matrix.
  • the second is the duodenum or jejunum of the gut and the third is the skin.
  • the organs are packed on ice in sterile containers immediately after animal slaughter and transported to the laboratory.
  • pancreas is treated using the protocol for islet removal, that is, the pancreatic duct is cannulated and Hank's solution containing 2mg/ml collagenase (Type X, Sigma) and 2% fetal calf serum is injected.
  • the two arteries that supply the pancreas, the celiac and the superior mesenteric are similarly perfused with a collagenase solution containing heparin to remove endothelium from the circulatory tree of the gland. Adequate cleaning of the pancreas may require heparinizing animals before slaughter.
  • a compression device is used to gently knead the organ as it is perfused and reperfused in a sterile chamber in the cold.
  • the collagenase solution is gradually diluted.
  • a fibrous network of ducts and vessels remains after collagenase digestion.
  • the fibrous material is freeze- dried and mechanically fractured in an OmnimixerTM shearing tube. After thawing, the particulates are washed again and sterilized in 5.0% peracetic acid.
  • the objective of the freezing and fracturing procedure is to provide matrix particulates of between 100 and 200 ⁇ m in diameter.
  • the size of the particulates is also determined by the maximum allowable thickness of a tissue graft made to a host. The thickness must be consistent with survival after implantation in vivo. A diffusion distance greater than 0.5mm is not desirable, because the graft must depend on diffusing tissue fluids for gas exchange and nutrients until it is vascularized.
  • the goal is to produce particulates of relatively uniform size from the frozen tissue by a mechanical process that will not melt the material by frictional heating.
  • Blending, grinding, crushing, and/or percussion in the cold at -30°C or below are methods which can be used.
  • the particulates are then combined into aggregates with small clusters of cultivated cells, or are used as microbeads in a cell bioreactor in which cells from islet cell cultures are seeded.
  • the cells attach to surfaces of the matrix microbeads in the bioreactor.
  • the last mentioned strategy is useful as a means of expanding islet cell cultures; it can also serve as a means for constituting pseudo-islets.
  • the second example of an organ processed for its matrix is the jejunum or duodenum which is mechanically scraped after opening.
  • the stratum compactum As described by Badylak, et al. , U.S. Patent Serial No. 4,902,508 (1990), the stratum compactum, about 100 ⁇ m thick, lying between luminal layers on one side and the muscular layers on the other, is delaminated from them, leaving an acellular collagenous connective tissue.
  • the washed stratum compactum is particularized after freeze-drying as described above.
  • the third organ, skin is stripped of epidermis and underlying adipose material and the dermis is sectioned into 100-200 ⁇ m thick sheets parallel to the dermal surface with a dermato e. It is then freeze-dried, particularized and washed in preparation for combination with cells or transplantation.
  • the sheets derived from the jejunum and the dermis can be made porous or perforated with a meshing machine or similar device so that they can be seeded with cells or pseudo-islets or both.
  • Aggregates can also be formed when suspensions of cultured cells are combined with matrix particulates in a transwell chamber, such as that produced by CostarTM.
  • the fluid in which the cells and particulates are suspended drains through the porous membrane that serves as the floor of the chamber and the cells are brought into close proximity with the particulates whose surfaces they attach to.
  • Secreted cell products provide the additional matrix that gives the mass of particulates coherence.
  • a flat porous collagen container or one made with a poly-1- lactate or other biopolymer, is fabricated and filled with the matrix particulates and adherent cells constituted in a bioreactor or other device.
  • the biopolymer container and its contents can then be maintained in a chamber whose floor is a transwell membrane in contact with nutrient medium.
  • the other method consists of crosslinking the - particulates non-toxically with transglutaminase in the presence of dermatan sulfate and fibronectin thereby forming three dimensional reconstituted tissues. Because this method is not damaging to cells, crosslinking can occur in the presence of cells.
  • the assembled constructs, that is three dimensional reconstituted tissues, are incubated at 37°C in a 5% C0 2 incubator and allowed to undergo differentiation in vitro in preparation for transplantation.

Abstract

Using connective tissues as starting materials, a method is described for producing matrix particulates. The invention includes an embodiment wherein the matrix particulates are seeded with living human cells or with cells of other species. Further, the invention encompasses fusing the particulates to constitute composites of various shapes, or holding them together in a porous container made of membranous biopolymers. The particulates or composites can be used as tissues for grafting or as model systems for research and testing. The invention also encompasses the spinning of threads in which the matrix particulates are components.

Description

PRODUCTION OF GRAFT TISSUE FROM EXTRACELLULAR MATRIX
Background of the Invention The use of synthetic materials such as polyester fiber (Dacron™) or polytetraflurorethylene (PTFE) (Teflon™) as implants designed to replace diseased or damaged body parts has been extensive. These materials have however, enjoyed limited success. This has been due to the poor biocompatibility of these materials which among other problems, frequently initiate persistent inflammatory reactions. Additionally, the failure of the body to integrate these materials, because they do not break down and do not lend themselves to remodeling by tissue cells that may come into contact with them, causes further problems.
Efforts to use animal or human materials have also been unsatisfactory when these materials are cross-linked by formaldehyde or glutaraldehyde, for example. The process of generalized aldehydic cross-linking renders biomaterials sufficiently unrecognizable to tissue cells so that normal remodeling and integration are not promoted. Similarly, other types of chemical processing of animal or human biomaterials, such as extraction with detergents, or hypertonic buffers or hypotonic buffers can alter them to the degree that they are ineffective in promoting angiogenesis and in stimulating repair and remodeling processes needed for the conversion of an implant into a functional substitute for the tissue or organ being replaced.
A third approach has been that of reconstituting tissue and organ equivalents from structural matrix components, such as collagen, for example, that have been extracted and purified and combined with specialized cells. The process depends upon interactions between the cells and matrix proteins that the cells condense and organize. While tissue-like constructs have been fabricated and been shown to somewhat resemble their natural counterparts, they do not readily develop the matrix complexity characteristic of the actual tissues they are meant to imitate. See, for example, U.S. Patent Nos. 4,485,096 and 4,485,097, E. Bell, 1984.
SιιiBwii_ry r>f the Invention
The present invention relates to a method of producing graft tissue by obtaining a desired connective tissue source and processing it to remove living cells without removing factors necessary for cell growth. The tissue is frozen or freeze dried and then fragmented, and the living cells removed to produce connective tissue matrix particulates. In the alternative, the tissue can be fragmented before freezing.
The invention also includes methods of producing graft tissue which comprise the above method with the additional steps, alone or in combination, of 1) again processing the connective tissue particulates to remove the cytoplasmic and nucleic acid components without removing the factors necessary for cell growth and differentiation; and 2) seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to or populate the connective tissue particulates.
In one embodiment of the invention, the matrix particulates are seeded with selected cultured human or other cells. The resulting cell populated material can be fused into composites of various shapes, with or without the addition of growth and differentiation factors. The present invention embodies a new method for preparing animal tissues as transplants designed to substitute for tissues or organs that are damaged or diseased. This is accomplished in such a way that their native complexity is preserved and thus allows them to be remodeled and integrated by the specialized cells with which they are brought into contact. In other words, because the matrix particulates of the present invention contain cell growth and differentiation stimulatory molecules, they provide the biomolecular signals needed for -in vivo tissue repair. In contrast to methods previously described, the method of the present invention avoids the use of harsh reagents such as high salt, or delipidation reagents such as butanol/ether or detergents. The use of such reagents in methods previously described is responsible for removing from the connective tissue a great many factors whose presence we consider essential for stimulating repair and remodeling processes needed for the conversion of an implant into a functional substitute for the tissue or organ being replaced.
Advanced methods in in vitro cell cultivation permit expansion of small numbers of differentiated cells into large cell banks. Tissue matrix vehicles that can direct the organization and differentiation of these specialized cells for delivery to the human recipient in the clinic are needed. The present invention can be used to bring a disease such as diabetes under control by engineering and implanting reconstituted tissues or composites populated by cells with the appropriate functional capacity to overcome the problems caused by absent or insufficient insulin biosynthesis or its regulated delivery. For example, particulates of the present invention can be combined in vitro with cells from the islets of Langerhans, or with undissociated islets, to form a composite which is then implanted under the kidney capsule. Further, cell-populated matrix composites may be implanted directly, for example by using a hypodermic syringe or similar devise to deliver the composite to the desired site. This invention similarly may be used to treat Parkinson's disease by providing the patient with a tissue containing dopamine producing cells. One can also plate nerve cells on the particulates and allow a composite to form. This would be useful in the repair of neural tissue defects. The method of this invention also has broad applications in the rebuilding of damaged or aberrant body structures such as skin, various tubular structures and skeletal structures such as bone, tendon and ligament. The invention may also be used to create connective tissue matrices to be used as tissue scaffolds which are populated by circulating cells after transplantation into the desired site. In one embodiment, the matrix particulates are mixed with a substance which can form porous membranous polymers containing the particulates, and then shaped. Matrix particulate-containing threads are one example of the many shapes which can be formed using particulates of the present invention. For example, the particulates can be mixed with collagen, or another bioabsorbable or nonbioabsorbable polymer, and extruded into a dehydration or coagulation bath containing absolute ethanol or acetone, or another dehydrating solution. The thread can also be subjected to dehydration by some other means, for example vacuum-drying. The particulates can also be coextruded with collagen or another polymer serving as a hollow fiber. Together, the particulates and the hollow fiber serve as a loaded hollow fiber with the particulates filling the core of the hollow polymer fiber. The threads produced in this manner can then be braided or woven to form fabrics or other complex constructs for implantation. In addition to the advantage provided by the high strength, flexibility and increased surface area of braided or woven threads, sleeves of the loaded hollow fiber threads can be made porous, thus allowing colonizing cells to occupy the surface of the thread and thereby contact the tissue matrix particles within the thread. In a further embodiment, the method of the present invention is used to produce matrix particulates from fetal skeletal elements derived from animal sources, prior to mineralization. These fetal matrix particulates can be combined with osteogenic cells in cylindrically shaped collagenous containers to form skeletal constructs. The collagenous external surface of the containers can be plated with a second cell type associated with periosteal tissue. In a similar manner, a composite derived from dermal matrix particulates, or from a sheet of previously frozen matrix that has been perforated, can be over-plated with keratinocytes to form a skin-like construct.
Detailed Description of The Invention The invention includes a method of producing graft tissue which comprises obtaining a desired connective tissue source, then processing it to remove living cells without removing factors necessary for cell growth and differentiation. The cell-free connective tissue source is frozen or freeze-dried, and fragmented, either before or after freezing or freeze-drying, to produce connective tissue particulates. In the alternative, the tissue can be frozen or freeze-dried after fragmentation. The cell- free connective tissue particulates can be used as an implant for host cells to populate. The freeze-dried connective tissue can also be used without fragmentation, but perforated before use. According to this embodiment, the cell-free tissue can be used in the form of perforated sheets or strips without fragmentation. The invention includes another method for producing graft tissue which comprises obtaining a desired connective tissue source and processing as above to remove living cells without removing factors necessary for cell growth and differentiation. The connective tissue source is frozen or freeze-dried, then fragmented to produce connective tissue particulates. The connective tissue particulates are seeded with cultivated cells under such conditions that the cells adhere to and populate the connective tissue particulates. In one embodiment of the present invention, the connective tissue particulates are seeded with cultivated cells and then packed into a preformed porous polymeric container. This method can also include the optional step of further processing the connective tissue particulates before they are seeded, in order to remove nucleic acids without removing other factors necessary for cell growth and differentiation. Further processing can include contacting the connective tissue particulates with nuclease preparations. The invention includes another method for producing graft tissue which comprises obtaining a desired connective tissue source and processing as above to remove living cells without removing factors necessary for cell growth and differentiation. The connective tissue source is then frozen or freeze-dried and fragmented to produce connective tissue particulates. In the alternative, the cells can be removed prior to fragmentation. The particulates are mixed with a porous polymer, such as collagen or other bioabsorbable or nonbioabsorbable polymers, then extruded to form threads composed of the polymer and the connective tissue particulates. The threads of the invention can be either mixed fiber (in which the thread is comprised of a mixture of the polymer and the cell matrix particulate) , or loaded hollow fiber (in which the thread is comprised of a core of cell matrix particulates surrounded by a porous polymer sleeve) . These threads are then braided or woven to form fabrics or other complex constructs for implantation. The sleeve of the loaded hollow fiber threads is porous, thus allowing colonizing cells to occupy the surface of the thread and thereby contact the tissue matrix particles within the thread.
The invention encompasses another method of producing graft tissue which comprises obtaining a desired connective tissue' source and processing to remove living cells without removing factors necessary for cell growth and differentiation. According to this method, the connective tissue source is frozen or freeze-dried, but not fragmented. Instead, the tissue is processed in the form of sheets or strips. These sheets or strips are frozen or freeze-dried, then thawed and perforated to allow cells to infiltrate the tissue. In one embodiment, the connective tissue sheets or strips are seeded with cultivated cells under such conditions that the cells adhere to and populate the sheets or strips. The seeded sheets or strips can be further shaped or molded to form useful graft tissue. In another embodiment of the subject invention, the sheets or strips can be implanted into a host without first seeding with cultivated cells. According to this embodiment, the sheets or strips would provide a site for host cells to populate.
Fragmentation of the desired tissue can be achieved by freezing or freeze-drying, and then mechanically blending the frozen or freeze-dried tissue or mechanically crushing it between rollers. The desired tissue can also be fragmented by blending the tissue without first freezing it. An optional nuclease treatment is carried out for the purpose of digesting the nucleic acids released when the cells and cell nuclei are ruptured. The connective tissue particulates are then washed and collected by the serial steps of centrifugation, resuspension, recentrifugation and resuspension.
The invention further encompasses a method wherein the connective tissue particulates obtained by the above methods are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates. One embodiment of this method includes an additional step of fusing the connective tissue particulates to form a composite using a fusing agent. The type of fusing agents which can be selected are known to one skilled in the art. In a preferred embodiment, in vitro cultivated cells are plated onto the connective tissue composite in a volume which will just cover the composite and allow transportation of nutrients. The cells are plated under conditions that allow the cells to populate or adhere to the connective tissue particulates. One or more than one cell type can be plated onto the composite.
The invention further includes a construct which is produced by any of the above methods, including a multi- cell construct.
The connective tissue source can be derived from bovine, ovine, porcine or marine animal connective tissues, as well as other species of vertebrates of invertebrates. The invention further includes connective tissues which are derived from a variety of body parts or tissues. In a preferred embodiment of the invention connective tissue is derived from embryonic or fetal tissues. Embryonic and fetal tissues are advantageous because they include various biomolecular factors which are present in normal tissue at different stages of cell development. The factors present in fetal tissues include, for example, factors necessary for cell division, differentiation and tissue morphogenesis. The connective tissue matrix particulates derived through the above methods can be seeded with selected cultured human or other cells. The resulting cell- populated matrix can be fused into composites of various shapes, with or without the addition of growth and differentiation factors.
In a preferred embodiment of the invention the matrix particulates are selected to match the tissue being fabricated. For example if a skin replacement is the objective, preferably dermal matrix would be particularized and a composite with dermal cells constructed. If neural tissue replacement is the goal, preferably embryonic or fetal central nervous system connective tissue matrix would be chosen for combination with the appropriate cells to form a composite.
The processing steps of the above methods are performed in order to remove cells from the selected animal tissues, thereby producing connective tissue matrix particulates. There are many methods known in the art for removing cells from connective tissue. The following are examples of some of these methods. These examples are not intended to be an exhaustive list, but are merely examples of some of the known methods. The choice of method and the sequence of treatments depend on the type of tissue being processed.
In one method for removing cells from the connective tissue, the tissue is scraped with a blade or blade-like instrument. The tissue can also be passed successively between parallel rollers, where the rollers are brought closer together in successive steps thereby squeezing out soft components including cells. The tissue can also be treated with enzymes, particularly nucleases. Additionally, the tissue is passed through a freeze-thaw, or freeze-dry-thaw cycle in order to disrupt the living cells. These methods can also be employed to remove remaining cytoplasmic and nuclear components in connective tissue particulates produced by fragmentation of the connective tissue source.
The freezing and/or freeze-drying, and fragmentation steps are done to produce particulates and to further free the tissue of undesirable components. Methods for sterilizing processed tissues are known to one skilled in the art and include contacting the tissue with a peracetic acid solution, preferably about a 0.5% solution, and washing the tissue in a sterile buffer, preferably sterile phosphate buffered saline. The tissue can then be freeze- dried by being brought to the temperature of liquid nitrogen, then fragmented under sterile conditions. Fragmentation at low temperature can be carried out in many ways known to those skilled in the art.
Fragmentation methods could include a shearing device, such as a mechanical blender, or mechanically crushing the tissue between rollers to yield particulates of such a size so as to allow for vascularization upon implantation. In a preferred embodiment of the invention, the particulates are between about 50 and about 300 micrometers in diameter, but for some applications the particulates can be as small as 5-10 microns. Depending on the starting tissue type, further nuclease cleaning and washes followed by centrifugation and resuspension in fresh phosphate buffered saline can be carried out in an effort to minimize the presence of components which are immunogenic.
In another embodiment of the invention the tissue can be dehydrated chemically with acetone, absolute alcohol or hydrophilic polymers such as carbowax, and then fragmented. In a preferred embodiment of the invention the particulates are further treated by seeding the matrix with cells. Preferably one would use human cells for populating the matrix, but the invention is not limited to hu an cells. In one embodiment the seeding process is carried out by rehydrating the matrix particulates using tissue culture medium, with or without growth and differentiation supplements added, and allowing the particulates to swell to equilibrium with their fluid environment.
In another embodiment of the invention the matrix particulates are populated with cells of one, or more than one phenotype in a bioreactor, spinner flask or other similar device. The number of cells used and the time of residence in the device depend on cell attachment time and the desired degree of coverage of the particulate by the cells. These parameters will vary depending on the type of cell used and the cell density required for the final product. The particular parameters for each cell type will be apparent to one skilled in the art. In a preferred embodiment of the invention the starting cell density is on the order of about 104 to about 10° cell per ml. In a further embodiment of the invention the particulates are fused into composites of various shapes with or without the addition of growth and differentiation factors. This step can be carried out on particulates which have been seeded with cells, or on particulates which do not contain cells. In the latter case the fused matrix composite can be seeded with cells after the particulates are fused into composites. The matrix composite, with or without cells, is then layered onto a synthetic porous membrane. Examples of a synthetic porous membrane, for illustrative purpose only and not to limit the invention in any way, include membranes made of polycarbonate, for example in a transwell arrangement, or a bioabsorbable polymer, such as a porous collagen sheet that lines a mold having a porous membrane for a bottom to hold the collagen sheet and permit passage of medium from below. The membrane may also be made of other bioabsorbable polymers such as poly-1-lactate. In one embodiment of the invention the particulates are layered in a single layer. In a preferred embodiment the layer is less than about 0.5 millimeters in thickness.
If the matrix has been seeded with cells, the thickness of the layer must be controlled in such a way so as to ensure that the necessary nutrients may flow to the cells. The seeding of the matrix is carried out by applying cells in suspension directly onto the particulate composite in a volume that will just cover the composite but not run off it, under such conditions that the cells populate the matrix. Non-limiting examples of a few of the ways in which the porosity of the composites can be controlled include: limiting cell growth, limiting crosslinking, and mechanically, by placing a brush-like device with spaced Teflon™ "hairs'1 onto the substrate prior to delivering the particulates to it. If the last expedient is used the sheet will form around the microposts or "hairs", thereby creating holes when the "hairs" are removed.
If the matrix is seeded with cells and then incubated for a period of time in tissue culture medium, the construct will be in the form of a coherent sheet that can be handled alone or, for example, by the porous collagen membrane on which it formed. In a preferred embodiment of the invention the incubation period is about 7-14 days. The collagen membrane can also be used to wrap the composite. The collagen membrane can be fixed to the composite, for example by suturing, so that a flat package is formed. The sheet can also be rolled around a shaft to form a tube at ∑.ny stage in its development after it becomes coherent. A further embodiment of the invention includes the use of multiple cell types combined with the composite by plating cells on either side of the composite, or by plating cells on the porous collagen membrane used to wrap the composite. Further, a layer of one cell type can be plated over a layer containing another cell type, or cells of different types may be plated together.
Still further the invention encompasses the case where the cell-laden particulates are packaged in a preformed porous collagen or other polymeric container of any desired shape. The container can be a rectangular box where, in a preferred embodiment, the box is not thicker than about 1.0mm. Additionally the invention discloses the use of concentric tubes of differing radii where, in a preferred embodiment, the radii would differ by only by about 1.0mm or less. It is also envisioned that other shapes can be used as well.
The containers can be reinforced by struts or other means to maintain uniform thickness. The frequency of the struts is preferably about 1-10 per mm square. The container can be made out of a collagen sheet with pores which are too small to allow particulates to escape. In a preferred embodiment, the pores measure about 30 to about 60 microns. After introduction of particulates through an end opening, the container can be sealed by suturing or other means.
In another embodiment of the present invention, the connective tissue particulates are formed into threads suitable for weaving or braiding. The threads can be woven into fabrics or other complex constructs for implantation, the braided or woven fabrics would provide a scaffold of matrix material for host cells to adhere to. In addition, the thread or fabrics produced from the threads, can be seeded with cells n vitro, as above, and then transplanted into the appropriate site in the host. The threads of this invention can be either of the mixed fiber, or the loaded hollow type. Mixed fiber threads are made by mixing connective tissue particulates with a bioabsorbable or nonbioabsorbable polymer, then extruding the mixture, using, for example, a spinnaret, to form a mixed thread. The hollow fiber thread comprises a core of connective tissue particles of this invention surrounded by a porous polymeric sleeve. The polymer used for producing the threads can be either bioabsorbable or nonbioabsorbable. In a preferred embodiment the polymer is collagen. After extrusion, threads of this invention are dehydrated and coagulated, for example by extrusion into a bath containing absolute alcohol, carbowax or acetone. The threads can then be annealed, for example by pulling the threads over rollers from the coagulation bath into an annealing bath containing a saline solution. The threads can then be dried and spooled, for example by pulling the threads over more rollers to dry, and then winding onto spools.
Exemplification
Animal sources are obtained for connective tissue matrix materials, such as organs, from porcine, bovine, ovine, marine or other animals. For example, to reconstitute an endocrine pancreas equivalent at least three organs can be used. The first is the pancreas itself, which would provide the tissue specificity of the matrix. The second is the duodenum or jejunum of the gut and the third is the skin. The organs are packed on ice in sterile containers immediately after animal slaughter and transported to the laboratory. The pancreas is treated using the protocol for islet removal, that is, the pancreatic duct is cannulated and Hank's solution containing 2mg/ml collagenase (Type X, Sigma) and 2% fetal calf serum is injected. In addition the two arteries that supply the pancreas, the celiac and the superior mesenteric, are similarly perfused with a collagenase solution containing heparin to remove endothelium from the circulatory tree of the gland. Adequate cleaning of the pancreas may require heparinizing animals before slaughter. A compression device is used to gently knead the organ as it is perfused and reperfused in a sterile chamber in the cold.
In the course of recirculation the collagenase solution is gradually diluted. A fibrous network of ducts and vessels remains after collagenase digestion. After washing in phosphate buffered saline, the fibrous material is freeze- dried and mechanically fractured in an Omnimixer™ shearing tube. After thawing, the particulates are washed again and sterilized in 5.0% peracetic acid.
The objective of the freezing and fracturing procedure is to provide matrix particulates of between 100 and 200 μm in diameter. The islet of Langerhans of the pancreas, responsible for secreting insulin and other hormones, itself measures between 100 and 200 μm. The size of the particulates is also determined by the maximum allowable thickness of a tissue graft made to a host. The thickness must be consistent with survival after implantation in vivo. A diffusion distance greater than 0.5mm is not desirable, because the graft must depend on diffusing tissue fluids for gas exchange and nutrients until it is vascularized. The goal is to produce particulates of relatively uniform size from the frozen tissue by a mechanical process that will not melt the material by frictional heating. Blending, grinding, crushing, and/or percussion in the cold at -30°C or below are methods which can be used. The particulates are then combined into aggregates with small clusters of cultivated cells, or are used as microbeads in a cell bioreactor in which cells from islet cell cultures are seeded. The cells attach to surfaces of the matrix microbeads in the bioreactor. The last mentioned strategy is useful as a means of expanding islet cell cultures; it can also serve as a means for constituting pseudo-islets.
The second example of an organ processed for its matrix is the jejunum or duodenum which is mechanically scraped after opening. As described by Badylak, et al. , U.S. Patent Serial No. 4,902,508 (1990), the stratum compactum, about 100 μm thick, lying between luminal layers on one side and the muscular layers on the other, is delaminated from them, leaving an acellular collagenous connective tissue. The washed stratum compactum is particularized after freeze-drying as described above.
Similarly the third organ, skin, is stripped of epidermis and underlying adipose material and the dermis is sectioned into 100-200 μm thick sheets parallel to the dermal surface with a dermato e. It is then freeze-dried, particularized and washed in preparation for combination with cells or transplantation. Alternatively the sheets derived from the jejunum and the dermis can be made porous or perforated with a meshing machine or similar device so that they can be seeded with cells or pseudo-islets or both.
Aggregates can also be formed when suspensions of cultured cells are combined with matrix particulates in a transwell chamber, such as that produced by Costar™. The fluid in which the cells and particulates are suspended drains through the porous membrane that serves as the floor of the chamber and the cells are brought into close proximity with the particulates whose surfaces they attach to. Secreted cell products provide the additional matrix that gives the mass of particulates coherence.
Two other approaches to giving the particulate-cell, or particulate-pseudo-islet combinations coherence to facilitate grafting as sheets are the following: A flat porous collagen container, or one made with a poly-1- lactate or other biopolymer, is fabricated and filled with the matrix particulates and adherent cells constituted in a bioreactor or other device. The biopolymer container and its contents can then be maintained in a chamber whose floor is a transwell membrane in contact with nutrient medium.
The other method consists of crosslinking the - particulates non-toxically with transglutaminase in the presence of dermatan sulfate and fibronectin thereby forming three dimensional reconstituted tissues. Because this method is not damaging to cells, crosslinking can occur in the presence of cells. The assembled constructs, that is three dimensional reconstituted tissues, are incubated at 37°C in a 5% C02 incubator and allowed to undergo differentiation in vitro in preparation for transplantation.
Equivalents Those skilled in the art will know, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. These and all other equivalents are intended to be encompassed by the following claims.

Claims

1. A method of producing graft tissue which comprises: a) freezing a connective tissue source; b) processing the connective tissue source to remove living cells without removing factors necessary for cell growth; and c) fragmenting the connective tissue to produce connective tissue particulates.
2. A method of Claim 1, which further comprises the additional step of: d) seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to the connective tissue particulates.
3. A method of producing graft tissue which comprises: a) freezing a connective tissue source; b) processing the connective tissue source to remove living cells without removing factors necessary for cell growth; c) fragmenting the connective tissue to produce connective tissue particulates; d) processing the connective tissue particulates further to remove the cytoplasmic and nuclear components without removing the factors necessary for cell growth; and e) seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to the connective tissue particulates.
4. A method of Claim 1, wherein the fragmentation of the connective tissue in step b comprises mechanically blending the frozen connective tissue.
5. A method of Claim 1, wherein the fragmentation of the connective tissue in step b comprises mechanical crushing between rollers.
6. A method of Claim 1, wherein the fragmentation of the connective tissue in step b is followed by enzymatic treatment to remove nucleic acids.
7. A method of Claim 1, wherein the connective tissue particulates are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates.
8. A method of Claim 7, wherein the connective tissue particulates are fused by a fusing agent to form a composite.
9. A method of Claim 2, wherein the connective tissue particulates are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates.
10. A method of Claim 9, wherein the connective tissue particulates are fused by a fusing agent to form a composite.
11. A method of Claim 10, wherein the cultivated cells are suspended and plated onto the composite in a volume which will just cover the composite and allow transportation of nutrients, under such conditions that the cells populate the connective tissue particulates.
12. A method of Claim 11, wherein more than one cell type is plated onto the composite.
13. A method of Claim 3, wherein the connective tissue particulates are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates.
14. A method of Claim 13, wherein the connective tissue particulates are fused by a fusing agent to form a composite.
15. A_ method of Claim 14, wherein the cultivated cells are suspended and plated onto the composite in a volume which will just cover the composite and allow transportation of nutrients, under such conditions that the cells populate the connective tissue particulates.
16. A method of Claim 15, wherein more than one cell type is plated onto the composite.
17. A method of Claim 2, wherein the connective tissue particulates upon being seeded with cultivated cells are packed into a preformed porous polymeric container.
18. A method of Claim 3, wherein the connective tissue particulates upon being seeded with cultivated cells are packed into a preformed porous polymeric container.
19. A construct produced by the method of Claim 1.
20. A construct produced by the method of Claim 2.
21. A construct produced by the method of Claim 3.
22. A construct produced by the method of Claim 7.
23. A construct produced by the method of Claim 8.
24. A construct produced by the method of Claim 9.
25. A construct produced by the method of Claim 10.
26. A construct produced by the method of Claim 11.
27. A construct produced by the method of Claim 13.
28. A construct produced by the method of Claim 14.
29. A construct produced by the method of Claim 15.
30. A multi cell construct produced by the method of Claim 12.
31. A multi cell construct produced by the method of Claim 16.
32. A method of producing a mixed particulate and polymer thread for use as a graft tissue which comprises: a) freezing a connective tissue source; b) processing the connective tissue source to remove living cells without removing factors necessary for cell growth; c) fragmenting the connective tissue to produce connective tissue particulates; and d) mixing the particulates with a polymer and extruding the mixture so as to form a mixed particulate and polymer thread.
33. A method of Claim 32, wherein the polymer is bioabsorbable.
34. A method of Claim 32, wherein the biopolymer is collagen.
35. A method of producing a loaded hollow porous polymer thread for use as graft tissue which comprises: a) freezing a connective tissue source; b) processing the connective tissue source to remove living cells without removing factors necessary for cell growth; c) fragmenting the connective tissue to produce connective tissue particulates; d) extruding the particulates inside a porous polymer sleeve so as to form a thread comprised of a core of connective tissue particulates surrounded by a porous polymer sleeve.
36. A method of Claim 35, wherein the polymer is bioabsorbable.
37. A method of Claim 35, wherein the polymer is collagen.
38. A thread comprised of connective tissue particulates and a porous polymer.
39. A thread of Claim 38 wherein the polymer is bioabsorbable.
40. A thread of Claim 38 wherein the polymer is collagen.
41. A thread comprised of a central core and an outer sleeve, wherein the central core is comprised of connective tissue particulates and the sleeve is comprised of a porous polymer.
42. A thread of Claim 41 wherein the polymer is bioabsorbable.
43. A thread of Claim 41 wherein the polymer is collagen.
44. A fabric produced by weaving threads comprised of connective tissue matrix and a porous polymer.
45. A fabric of Claim 44 wherein the polymer is bioabsorbable.
46. A fabric of Claim 44 wherein the polymer is collagen.
47. A method of producing sheets of acellular tissue matrix for use as graft tissue which comprises: a) freezing a connective tissue source; b) processing the connective tissue source to remove living cells without removing factors necessary for cell growth, thereby producing a sheet of acellular connective tissue matrix; and c) perforating the sheets produced in step b) , thereby producing a sheet of acellular connective tissue matrix for use as graft tissue. AME-NDED CLAIMS
[received by the International Bureau on 13 January 1994 (13.01.94); original claims 1,3-6,32,34 and 35 amended; other claims unchanged (7 pages)]
1. A method for producing graft tissue, which comprises the steps of: a) freezing a connective tissue source having living cells, whereby the living cells are disrupted to form cell remnants; b) processing the connective tissue source to remove the cell remnants from the connective tissue source without removing factors necessary for cell growth to form a processed connective tissue source; and c) fragmenting the processed connective tissue source to produce connective tissue particulates, thereby producing graft tissue.
2. A method of Claim 1, which further comprises the additional step of: d) seeding the connective tissue particulates with cultivated cells under such conditions that the cells adhere to the connective tissue particulates.
3. A method for producing graft tissue, which comprises the steps of: a) freezing a connective tissue source having living cells, whereby the living cells are disrupted to form cell remnants; b) processing the connective tissue source to remove the cell remnants from the connective tissue source without removing factors necessary for cell growth to form processed connective tissue source; c) fragmenting the processed connective tissue source; d) processing the connective tissue source further to remove cytoplasmic and nuclear components without removing factors necessary for cell growth to form connective tissue particulates; and e) exposing the connective tissue particulates to cultivated cells under such conditions that the cells adhere to the connective tissue particulates, thereby producing graft tissue.
4. A method of Claim 1, wherein the fragmentation of the connective tissue in step c comprises mechanically cutting up the frozen connective tissue.
5. A method of Claim 1, wherein the fragmentation of the connective tissue in step c comprises mechanical crushing between rollers.
6. A method of Claim 1, wherein the fragmentation of the connective tissue in step c is followed by enzymatic treatment to remove nucleic acids.
7. A method of Claim 1, wherein the connective tissue particulates are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates.
8. A method of Claim 7, wherein the connective tissue particulates are fused by a fusing agent to form a composite.
9. A method of Claim 2, wherein the connective tissue particulates are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates. 10. A method of Claim 9, wherein the connective tissue particulates are fused by a fusing agent to form a composite.
11. A method of Claim 10, wherein the cultivated cells are suspended and plated onto the composite in a volume which will just cover the composite and allow transportation of nutrients, under such conditions that the cells populate the connective tissue particulates.
12. A method of Claim 11, wherein more than one cell type is plated onto the composite.
13. A method of Claim 3, wherein the connective tissue particulates are layered onto a synthetic porous membrane to a thickness which allows diffusion of nutrients to all the connective tissue particulates.
14. A method of Claim 13, wherein the connective tissue particulates are fused by a fusing agent to form a composite.
15. A method of Claim 14, wherein the cultivated cells are suspended and plated onto the composite in a volume which will just cover the composite and allow transportation of nutrients, under such conditions that the cells populate the connective tissue particulates.
16. A method of Claim 15, wherein more than one cell type is plated onto the composite. 17. A method of Claim 2, wherein the connective tissue particulates upon being seeded with cultivated cells are packed into a preformed porous polymeric container.
18. A method of Claim 3, wherein the connective tissue
-» 5 particulates upon being seeded with cultivated cells are packed into a preformed porous polymeric container.
19. A construct produced by the method of Claim 1.
20. A construct produced by the method of Claim 2.
21. A construct produced by the method of Claim 3.
10 22. A construct produced by the method of Claim 7.
23. A construct produced by the method of Claim 8.
24. A construct produced by the method of Claim 9.
25. A construct produced by the method of Claim 10.
26. A construct produced by the method of Claim 11.
15 27. A construct produced by the method of Claim 13.
28. A construct produced by the method of Claim 14.
29. A construct produced by the method of Claim 15.
30. A multi-cell construct produced by the method of Claim 12. 31. A multi-cell construct produced by the method of Claim 16.
32. A method for producing a mixed particulate and polymer thread for use as a graft tissue, which comprises the steps of: a) freezing a connective tissue source having living cells, whereby said living cells are disrupted to form cell remnants; b) processing the connective tissue source to remove the cell remnants from the connective tissue source without removing factors necessary for cell growth to form processed connective tissue source; c) fragmenting the processed connective tissue source to form connective tissue particulates; d) mixing the connective tissue particulates with a polymer, whereby a mixture is formed; and e) extruding the mixture so as to form a mixed particulate and polymer thread, thereby producing the thread for use as graft tissue.
33. A method of Claim 32, wherein the polymer is bioabsorbable.
34. A method of Claim 32, wherein the polymer is collagen.
35. A method for producing a loaded hollow porous polymer thread for use as a graft tissue, which comprises the steps of: a) freezing a connective tissue source having living cells, whereby the living cells are disrupted to form cell remnants; b) processing the connective tissue source to remove the cell remnants from the connective tissue source without removing factors necessary for cell growth; c) fragmenting the connective tissue to produce 5 connective tissue particulates; and d) extruding the connective tissue particulates into a porous polymer sleeve so as to form a thread comprised of a core of connective tissue particulates surrounded by a porous polymer sleeve, 0 thereby producing the thread for use as graft tissue.
36. A method of Claim 35, wherein the polymer is bioabsorbable.
37. A method of Claim 35, wherein the polymer is collagen.
15 38. A thread comprised of connective tissue particulates and a porous polymer.
39. A thread of Claim 38 wherein the polymer is bioabsorbable.
40. A thread of Claim 38 wherein the polymer is collagen.
20 41. A thread comprised of a central core and an outer sleeve, wherein the central core is comprised of connective tissue particulates and the sleeve is comprised of a porous polymer.
42. A thread of Claim 41 wherein the polymer is 25 bioabsorbable. 43. A thread of Claim 41 wherein the polymer is collagen.
44. A fabric produced by weaving threads comprised of connective tissue matrix and a porous polymer.
45. A fabric of Claim 44 wherein the polymer is bioabsorbable.
46. A fabric of Claim 44 wherein the polymer is collagen.
47. A method of producing sheets of acellular tissue matrix for use as graft tissue which comprises: a) freezing a connective tissue source; b) processing the connective tissue source to remove living cells without removing factors necessary for cell growth, thereby producing a sheet of acellular connective tissue matrix; and c) perforating the sheets produced in step b) , thereby producing a sheet of acellular connective tissue matrix for use as graft tissue.
PCT/US1993/007364 1992-08-07 1993-08-05 Production of graft tissue from extracellular matrix WO1994003584A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP93919888A EP0656939B1 (en) 1992-08-07 1993-08-05 Production of graft tissue from extracellular matrix
DE69333466T DE69333466T2 (en) 1992-08-07 1993-08-05 PRODUCTION OF TRANSPLANT TISSUE FROM EXTRACELLULAR MATRIX
JP6505561A JPH07509638A (en) 1992-08-07 1993-08-05 Production of graft tissue from extracellular matrix

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US92688592A 1992-08-07 1992-08-07
US07/926,885 1992-08-07

Publications (1)

Publication Number Publication Date
WO1994003584A1 true WO1994003584A1 (en) 1994-02-17

Family

ID=25453844

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/007364 WO1994003584A1 (en) 1992-08-07 1993-08-05 Production of graft tissue from extracellular matrix

Country Status (6)

Country Link
US (1) US5893888A (en)
EP (1) EP0656939B1 (en)
JP (2) JPH07509638A (en)
CA (1) CA2141851A1 (en)
DE (1) DE69333466T2 (en)
WO (1) WO1994003584A1 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996014452A1 (en) * 1994-11-02 1996-05-17 Tissue Engineering, Inc. Apparatus and method for spinning and processing collagen fiber
WO1996015818A1 (en) * 1994-11-22 1996-05-30 Tissue Engineering, Inc. Biopolymer foams having extracellular matrix particulates
US5891558A (en) * 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
US5911942A (en) * 1995-11-02 1999-06-15 Tissue Engineering, Inc. Method for spinning and processing collagen fiber
WO1999051719A1 (en) * 1998-04-07 1999-10-14 Tissue Engineering, Inc. Methods and apparatus for the conditioning of cartilage replacement tissue
CN1061812C (en) * 1996-04-01 2001-02-14 胡杰 Preparation method of cell epimatrix used as cell planting frame and implant
EP1087756A1 (en) * 1998-06-19 2001-04-04 Lifecell Corporation Particulate acellular tissue matrix
WO2001091820A1 (en) * 2000-05-29 2001-12-06 Augustinus Bader Method for producing a bio-artificial transplant
EP1416876A2 (en) * 2001-07-16 2004-05-12 Depuy Products, Inc. Porous delivery scaffold and method
EP1425024A2 (en) * 2001-07-16 2004-06-09 Depuy Products, Inc. Porous extracellular matrix scaffold and method
US7358284B2 (en) 1998-06-19 2008-04-15 Lifecell Corporation Particulate acellular tissue matrix
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
USRE42208E1 (en) 2003-04-29 2011-03-08 Musculoskeletal Transplant Foundation Glue for cartilage repair
US8292968B2 (en) 2004-10-12 2012-10-23 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
WO2013096249A1 (en) * 2011-12-20 2013-06-27 Lifecell Corporation Sheet tissue products
US9271821B2 (en) 2012-01-24 2016-03-01 Lifecell Corporation Elongated tissue matrices
US9549805B2 (en) 2011-12-20 2017-01-24 Lifecell Corporation Flowable tissue products
US9701940B2 (en) 2005-09-19 2017-07-11 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
EP4070824A1 (en) 2021-04-09 2022-10-12 Regen i Göteborg AB Marine scaffolds for human tissue generation

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334872B1 (en) 1994-02-18 2002-01-01 Organogenesis Inc. Method for treating diseased or damaged organs
US20020095218A1 (en) * 1996-03-12 2002-07-18 Carr Robert M. Tissue repair fabric
US6998418B1 (en) 1996-11-05 2006-02-14 Gp Medical, Inc. Acellular biological material chemically treated with genipin
US6545042B2 (en) 1996-11-05 2003-04-08 Gp Medical Acellular biological material chemically treated with genipin
JP4356053B2 (en) * 1998-06-05 2009-11-04 オルガノジェネシス インク． Bioengineered vascular graft support prosthesis
MXPA00012064A (en) * 1998-06-05 2003-04-22 Organogenesis Inc Bioengineered tubular graft prostheses.
MXPA00012062A (en) * 1998-06-05 2003-04-22 Organogenesis Inc Bioengineered flat sheet graft prostheses.
JP4341050B2 (en) * 1998-06-05 2009-10-07 オルガノジェネシス インク． Vascular graft prosthesis made by bioengineering
MXPA03002414A (en) * 2000-09-18 2004-07-08 Organogenesis Inc Bioengineered flat sheet graft prosthesis and its use.
AU2002322255A1 (en) * 2001-06-15 2003-01-02 The Cleveland Clinic Foundation Tissue engineered mitral valve chrodae and methods of making and using same
JP4197160B2 (en) * 2001-07-16 2008-12-17 デピュイ・プロダクツ・インコーポレイテッド Supporting scaffold materials and methods for cartilage repair and regeneration
JP2003193328A (en) * 2001-12-19 2003-07-09 Nipro Corp Method of production for collagen monofilament
JP2004305260A (en) * 2003-04-02 2004-11-04 Olympus Corp Biological tissue prosthesis and production method thereof
US7488348B2 (en) * 2003-05-16 2009-02-10 Musculoskeletal Transplant Foundation Cartilage allograft plug
US7097579B2 (en) 2003-10-15 2006-08-29 Borgwarner Inc. Pivoting chain guide and tensioner assembly
CA2544726C (en) 2003-11-07 2018-06-26 University Of Connecticut Artificial tissue systems and uses thereof
US9138445B2 (en) * 2005-03-09 2015-09-22 Cook Biotech Incorporated Medical graft materials with adherent extracellular matrix fibrous mass
JP4356654B2 (en) * 2005-06-02 2009-11-04 ニプロ株式会社 Method for producing collagen single yarn
JP5540301B2 (en) * 2005-09-20 2014-07-02 独立行政法人物質・材料研究機構 Porous substrate, method for producing the same, and method of using the porous substrate
CA2693613C (en) * 2007-07-10 2018-01-23 Lifecell Corporation Acellular tissue matrix compositions for tissue repair
US8469779B1 (en) 2009-01-02 2013-06-25 Lifecell Corporation Method for debristling animal skin
US9597432B2 (en) * 2010-03-01 2017-03-21 Fujifilm Corporation Cell construct comprising polymer blocks having biocompatibility and cells
US9089523B2 (en) 2011-07-28 2015-07-28 Lifecell Corporation Natural tissue scaffolds as tissue fillers
BR112015000547B1 (en) 2012-07-13 2020-11-10 Lifecell Corporation method for treating tissue
EP2900288B1 (en) 2012-09-26 2018-01-31 Lifecell Corporation Processed adipose tissue
US9592254B2 (en) 2013-02-06 2017-03-14 Lifecell Corporation Methods for localized modification of tissue products
US10130288B2 (en) 2013-03-14 2018-11-20 Cell and Molecular Tissue Engineering, LLC Coated sensors, and corresponding systems and methods
US10405961B2 (en) 2013-03-14 2019-09-10 Cell and Molecular Tissue Engineering, LLC Coated surgical mesh, and corresponding systems and methods
EP3556406B1 (en) 2013-05-07 2021-12-22 National University Corporation Tokyo Medical and Dental University Method for producing particulate decellularized tissue
MX2016001247A (en) 2013-07-30 2016-08-17 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same.
SG11201702531TA (en) * 2014-10-10 2017-04-27 Orthocell Ltd Collagen construct and method for producing the collagen construct
US9238090B1 (en) 2014-12-24 2016-01-19 Fettech, Llc Tissue-based compositions
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
AU2017274190A1 (en) 2016-06-03 2018-12-13 Lifecell Corporation Methods for localized modification of tissue products
RU2627844C1 (en) * 2016-10-24 2017-08-14 Общество С Ограниченной Ответственностью "Ниармедик Плюс" Method for obtaining suspensional form of a ruled decellularized extracellular matrix
JP2020501660A (en) 2016-12-22 2020-01-23 ライフセル コーポレーションＬｉｆｅＣｅｌｌ Ｃｏｒｐｏｒａｔｉｏｎ Apparatus and method for cryocutting tissue
CN110664509A (en) * 2019-10-21 2020-01-10 南方医科大学 Ear implanting bracket and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358506A2 (en) * 1988-09-08 1990-03-14 MARROW-TECH INCORPORATED (a Delaware corporation) Three-dimensional cell and tissue culture system

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4642292A (en) * 1979-10-29 1987-02-10 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method for isolation of connective tissue biomatrix
US4501815A (en) * 1979-10-29 1985-02-26 Albert Einstein College Of Medicine Of Yeshiva University Article for culturing differentiated cells
US4505266A (en) * 1981-10-26 1985-03-19 Massachusetts Institute Of Technology Method of using a fibrous lattice
US4485096A (en) * 1982-02-26 1984-11-27 Massachusetts Institute Of Technology Tissue-equivalent and method for preparation thereof
US4485097A (en) * 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
US4661111A (en) * 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4645669A (en) * 1982-10-04 1987-02-24 Albert Einstein College Of Medicine Of Yeshiva University Culturing and emplacement of differentiated cells in vivo
US4801299A (en) * 1983-06-10 1989-01-31 University Patents, Inc. Body implants of extracellular matrix and means and methods of making and using such implants
US4837285A (en) * 1984-03-27 1989-06-06 Medimatrix Collagen matrix beads for soft tissue repair
GB8618374D0 (en) * 1986-07-28 1986-09-03 Hsc Res Dev Corp Biological vascular prostheses
US4795459A (en) * 1987-05-18 1989-01-03 Rhode Island Hospital Implantable prosthetic device with lectin linked endothelial cells
FR2617488B1 (en) * 1987-07-01 1990-03-09 Tab PROCESS FOR THE MANUFACTURE OF ORGANIZED COLLAGEN STRUCTURES, PARTICULARLY OF HUMAN ORIGIN, AND ORGANIZED COLLAGEN STRUCTURES THEREOF
US4969912A (en) * 1988-02-18 1990-11-13 Kelman Charles D Human collagen processing and autoimplant use
US5201745A (en) * 1988-03-15 1993-04-13 Imedex Visceral surgery patch
US5110604A (en) * 1988-06-30 1992-05-05 Collagen Corporation Processes for producing collagen matrixes and methods of using same
US5024841A (en) * 1988-06-30 1991-06-18 Collagen Corporation Collagen wound healing matrices and process for their production
US4950483A (en) * 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
US4902508A (en) * 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US5171273A (en) * 1989-01-13 1992-12-15 University Of Medicine And Dentistry Of New Jersey Synthetic collagen orthopaedic structures such as grafts, tendons and other structures
US5026381A (en) * 1989-04-20 1991-06-25 Colla-Tec, Incorporated Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit
US5378469A (en) * 1990-04-06 1995-01-03 Organogenesis, Inc. Collagen threads
US5192312A (en) * 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
US5562946A (en) * 1994-11-02 1996-10-08 Tissue Engineering, Inc. Apparatus and method for spinning and processing collagen fiber

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358506A2 (en) * 1988-09-08 1990-03-14 MARROW-TECH INCORPORATED (a Delaware corporation) Three-dimensional cell and tissue culture system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SHERWOOD GITHENS III, ET AL.: "DUCTS OF THE RAT PANCREAS IN AGAROSE MATRIX CULTURE", IN VITRO, vol. 16, no. 9, September 1980 (1980-09-01), pages 797 - 808 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5562946A (en) * 1994-11-02 1996-10-08 Tissue Engineering, Inc. Apparatus and method for spinning and processing collagen fiber
US5851290A (en) * 1994-11-02 1998-12-22 Tissue Engineering, Inc. Apparatus for spinning and processing collagen fiber
WO1996014452A1 (en) * 1994-11-02 1996-05-17 Tissue Engineering, Inc. Apparatus and method for spinning and processing collagen fiber
WO1996015818A1 (en) * 1994-11-22 1996-05-30 Tissue Engineering, Inc. Biopolymer foams having extracellular matrix particulates
US5709934A (en) * 1994-11-22 1998-01-20 Tissue Engineering, Inc. Bipolymer foams having extracellular matrix particulates
US5891558A (en) * 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
US5948429A (en) * 1994-11-22 1999-09-07 Tissue Engineering, Inc. Methods for preparing biopolymer foams
US5911942A (en) * 1995-11-02 1999-06-15 Tissue Engineering, Inc. Method for spinning and processing collagen fiber
CN1061812C (en) * 1996-04-01 2001-02-14 胡杰 Preparation method of cell epimatrix used as cell planting frame and implant
WO1999051719A1 (en) * 1998-04-07 1999-10-14 Tissue Engineering, Inc. Methods and apparatus for the conditioning of cartilage replacement tissue
EP1087756A1 (en) * 1998-06-19 2001-04-04 Lifecell Corporation Particulate acellular tissue matrix
EP1087756A4 (en) * 1998-06-19 2006-03-15 Lifecell Corp Particulate acellular tissue matrix
US7358284B2 (en) 1998-06-19 2008-04-15 Lifecell Corporation Particulate acellular tissue matrix
WO2001091820A1 (en) * 2000-05-29 2001-12-06 Augustinus Bader Method for producing a bio-artificial transplant
EP1416876A2 (en) * 2001-07-16 2004-05-12 Depuy Products, Inc. Porous delivery scaffold and method
EP1425024A2 (en) * 2001-07-16 2004-06-09 Depuy Products, Inc. Porous extracellular matrix scaffold and method
EP1416876A4 (en) * 2001-07-16 2007-04-18 Depuy Products Inc Porous delivery scaffold and method
EP1425024A4 (en) * 2001-07-16 2007-04-18 Depuy Products Inc Porous extracellular matrix scaffold and method
USRE42208E1 (en) 2003-04-29 2011-03-08 Musculoskeletal Transplant Foundation Glue for cartilage repair
USRE43258E1 (en) 2003-04-29 2012-03-20 Musculoskeletal Transplant Foundation Glue for cartilage repair
US7901457B2 (en) 2003-05-16 2011-03-08 Musculoskeletal Transplant Foundation Cartilage allograft plug
US8221500B2 (en) 2003-05-16 2012-07-17 Musculoskeletal Transplant Foundation Cartilage allograft plug
US8292968B2 (en) 2004-10-12 2012-10-23 Musculoskeletal Transplant Foundation Cancellous constructs, cartilage particles and combinations of cancellous constructs and cartilage particles
US7815926B2 (en) 2005-07-11 2010-10-19 Musculoskeletal Transplant Foundation Implant for articular cartilage repair
US9701940B2 (en) 2005-09-19 2017-07-11 Histogenics Corporation Cell-support matrix having narrowly defined uniformly vertically and non-randomly organized porosity and pore density and a method for preparation thereof
US7871440B2 (en) 2006-12-11 2011-01-18 Depuy Products, Inc. Unitary surgical device and method
US7837740B2 (en) 2007-01-24 2010-11-23 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US8906110B2 (en) 2007-01-24 2014-12-09 Musculoskeletal Transplant Foundation Two piece cancellous construct for cartilage repair
US8435551B2 (en) 2007-03-06 2013-05-07 Musculoskeletal Transplant Foundation Cancellous construct with support ring for repair of osteochondral defects
AU2012355463C1 (en) * 2011-12-20 2016-09-22 Lifecell Corporation Sheet tissue products
EP3842078A1 (en) * 2011-12-20 2021-06-30 LifeCell Corporation Sheet tissue products
AU2012355463B2 (en) * 2011-12-20 2016-05-19 Lifecell Corporation Sheet tissue products
US9532863B2 (en) 2011-12-20 2017-01-03 Lifecell Corporation Sheet tissue products
US9549805B2 (en) 2011-12-20 2017-01-24 Lifecell Corporation Flowable tissue products
WO2013096249A1 (en) * 2011-12-20 2013-06-27 Lifecell Corporation Sheet tissue products
US9913705B2 (en) 2011-12-20 2018-03-13 Lifecell Corporation Flowable tissue products
US10022214B2 (en) 2011-12-20 2018-07-17 Lifecell Corporation Sheet tissue products
US10722339B2 (en) 2011-12-20 2020-07-28 Lifecell Corporation Flowable tissue products
EP3549615A1 (en) * 2011-12-20 2019-10-09 LifeCell Corporation Sheet tissue products
EP3501558A1 (en) * 2011-12-20 2019-06-26 LifeCell Corporation Flowable tissue products
US10327884B2 (en) 2012-01-24 2019-06-25 Lifecell Corporation Elongated tissue matrices
US9271821B2 (en) 2012-01-24 2016-03-01 Lifecell Corporation Elongated tissue matrices
US10077420B2 (en) 2014-12-02 2018-09-18 Histogenics Corporation Cell and tissue culture container
US11555172B2 (en) 2014-12-02 2023-01-17 Ocugen, Inc. Cell and tissue culture container
EP4070824A1 (en) 2021-04-09 2022-10-12 Regen i Göteborg AB Marine scaffolds for human tissue generation
WO2022214693A1 (en) 2021-04-09 2022-10-13 Regen I Göteborg Ab Marine scaffolds for human tissue generation

Also Published As

Publication number Publication date
JP2003047652A (en) 2003-02-18
JPH07509638A (en) 1995-10-26
EP0656939B1 (en) 2004-03-31
EP0656939A1 (en) 1995-06-14
US5893888A (en) 1999-04-13
DE69333466T2 (en) 2004-08-19
DE69333466D1 (en) 2004-05-06
CA2141851A1 (en) 1994-02-17

Similar Documents

Publication Publication Date Title
US5893888A (en) Method and construct for producing graft tissue from extracellular matrix
US5800537A (en) Method and construct for producing graft tissue from an extracellular matrix
JP3808900B2 (en) Biological material composed of a three-dimensional biocompatible and biodegradable matrix comprising an effective culture of bone marrow stem cells partially or fully differentiated into connective tissue cells and a hyaluronic acid derivative
US7887843B2 (en) Method for in vitro production of three-dimensional vital cartilage tissue and use thereof as transplant material
JP2820796B2 (en) Biotherapeutic cell-coated microspheres
US6962814B2 (en) Decellularized tissue engineered constructs and tissues
AU2001284968A1 (en) Decellularized tissue engineered constructs and tissues
CN102076366A (en) Tissue engineered blood vessel
WO2014114043A1 (en) Cell matrix modified tissue engineering nerve graft for repairing peripheral nerve injury and preparation method thereof
WO2010111263A1 (en) Tissue engineering scaffolds and methods of use
KR20140033057A (en) Cell-synthesized particles
Griffon et al. Evaluation of vacuum and dynamic cell seeding of polyglycolic acid and chitosan scaffolds for cartilage engineering
CN113677700A (en) Cell structure and method for producing cell structure
CN101195044A (en) Tissue engineered fine particle tissue and method for preparing the same
EP1335735A1 (en) Vascularised tissue graft
CN110464877A (en) A kind of preparation method and its effect evaluation method of acellular nerve allografts
Kumaresan et al. Development of Human Umbilical cord based scaffold for tissue engineering application
JP4898068B2 (en) Method for making recipient-specific tissue graft or tissue implant
Wang et al. Research Article CNS Organoid Surpasses Cell-Laden Microgel Assembly to Promote Spinal Cord Injury Repair
Hardingham et al. Cell Culture in Tissue Engineering
KR20220125958A (en) Decellularization method of porcine stomach mucosa tissue, composition for producing scaffold and tissue culture method for culturing gastric tissue or gastric cancer tissue
JP2006075121A (en) Method for producing culture graft
AU2001283687A1 (en) Vascularised tissue graft
CA2861285A1 (en) Decellularized tissue engineered constructs and tissues

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1993919888

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2141851

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1993919888

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1993919888

Country of ref document: EP